BioNTech's Bispecific Antibody BNT-327 Shows Promise in Triple-Negative Breast Cancer
核心洞察
BioNTech's BNT-327, a bispecific antibody targeting PD-L1 (搜索) and VEGF (搜索), has demonstrated positive early results in patients with triple-negative breast cancer.
The bispecific antibody builds on the success of checkpoint inhibitors like Keytruda, potentially representing the next generation of immunotherapy drugs.
Early trial data, presented at the San Antonio Breast Cancer Symposium, suggest BNT-327 could become a critical component in treating triple-negative breast cancer.
Researchers may have found a promising candidate for the next generation of immunotherapy drugs: bispecific antibodies targeting PD1 or PD-L1 (搜索) and VEGF (搜索). A small early trial on BioNTech's bispecific compound, BNT-327, presented at the San Antonio Breast Cancer Symposium, showed positive results in patients with triple-negative breast cancer. These findings suggest BNT-327 could become a critical part of how triple-negative breast cancer, and potentially other cancers, are treated.
This research builds on the discovery of checkpoint inhibitors in the 1990s, which BioNTech co-founder and CMO Özlem Türeci called "transformative" in oncology. Drugs like Merck’s Keytruda stimulate the immune system to find and kill cancer cells and have become a mainstay in treating many cancer types. However, there's room for improvement, leading to the search for next-generation checkpoint inhibitors. Türeci believes PD-L1 (搜索) or PD1 and anti-VEGF (搜索) bispecifics represent this advancement.
The potential of these antibodies gained attention when Summit Therapeutics released data showing their PD1 and VEGF (搜索) bispecific antibody outperformed Keytruda in a Phase 3 trial in advanced lung cancer (搜索). Experts described the results as "striking" and "impressive," while also recommending caution until investigators can confirm the drug extends overall survival.